|Nombre||Título||Paga||Ejecutado||Año de nacimiento|
|Mr. David L. Hallal||Executive Chairman of the Board||254,38k||N/A||1966|
|Dr. Diana M. Brainard M.D.||CEO & Director||978,99k||N/A||1971|
|Mr. Vikas Sinha C.A., CPA, M.B.A.||President, CFO & Director||536,21k||N/A||1963|
|Mr. Edward Miller J.D.||General Counsel & Secretary||618,39k||N/A||1965|
|Mr. Brett R. Hagen||Chief Accounting Officer||N/A||N/A||1973|
|Mr. Dana M. Alexander||Senior Vice President of Technical Operations||N/A||N/A||1976|
|Dr. Ann M. Leen Ph.D.||Chief Scientific Officer||N/A||N/A||1977|
|Ms. Sonia Choi||Senior Vice President of Corporate Affairs & Investor Relations||N/A||N/A||N/A|
|Mr. Ugo Capolino Perlingieri||Head & GM of Europe and Middle East Operations||N/A||N/A||N/A|
|Ms. Cintia Piccina Pharm.D.||Chief Commercial Officer||N/A||N/A||1973|
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
El ISS Governance QualityScore de AlloVir, Inc., a día 1 de noviembre de 2023, es 10. Las puntuaciones base son Auditoría: 8; Tablero: 9; Derechos de los accionistas: 8; Compensación: 10.